Pennant Group (1ZU) AI Stock Analysis

0 Followers

Pennant Group

(Frankfurt:1ZU)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Broad-based growthStrong growth across revenue, admissions, and census indicates expanding demand and effective execution in core healthcare services. Broad-based gains reduce reliance on a single operating area and provide a durable foundation for continued scale, investment, and earnings growth.

Negative Factors

Recent margin compressionRecent margin compression suggests that revenue growth is facing higher cost pressure and producing less operating leverage. If this persists, it could limit earnings conversion, reduce the benefits of scale, and make future growth more dependent on continued execution and cost control.

Pennant Group (1ZU) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.29B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 35.4
Beta (1Y): 0.26
Revenue Growth: 32.03%
EPS Growth: 26.19%
Country: Germany
Employees: 9,700
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

Pennant Group Business Overview & Revenue Model

Company Description

The Pennant Group, Inc. is a U.S.-based healthcare provider, delivering a diverse range of services through two core divisions: Home Health and Hospice Services, and Senior Living Services. The company's Home Health segment offers in-home clinical su...

Pennant Group Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-13.51%|Next Earnings Date:Mar 03, 2027

Earnings Call SentimentPositive

The call was positive overall, with strong revenue, EBITDA, EPS, admissions, census, clinical-quality, acquisition, and integration performance, along with reaffirmed full-year guidance. The main negatives were broad-based elevated benefits costs, short-term senior living occupancy and leadership-capacity challenges, lower Southeast home health revenue per episode, transition disruption, and management's concerns about insufficient reimbursement and regulatory burdens.

Positive Updates

Strong Third-Quarter Financial Performance

Q3 revenue was $302.3 million, up 32% year over year. Adjusted EBITDA was $24.7 million, up 42.4%; adjusted EBITDA prior to NCI was $26.1 million, up 44%; and adjusted diluted EPS was $0.35, up 16.7%.

Negative Updates

Elevated Employee Benefits Costs

Higher-than-anticipated employee benefits costs created additional margin pressure and modestly impacted Q3 earnings. The impact was approximately 50 basis points of revenue, was broad-based across home health and hospice, senior living, and services, and management anticipates a similar increase in Q4.

Company Guidance

Management reaffirmed its full-year guidance and said it expects to hit its annual guidance, with the Amedisys and UnitedHealth integration expected to be completed in Q4 and disruption potentially modestly impacting results through the end of the year. Benefits expense was about 50 bps of revenue in Q3, and management anticipates similar in Q4. Senior living occupancy recovery is expected to make Q4 “a step in the right direction,” with a 9-quarter optimization period and 3 to 4 quarters as the expected timeline to get to accretive for communities that are significantly distressed; management also sees the opportunity to turn this into a real positive for 2027.

Pennant Group Risk Analysis

Pennant Group disclosed 42 risk factors in its most recent earnings report. Pennant Group reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Pennant Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1ZU against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADUS	83Outperform	$2.35B	20.91	9.81%	―	11.53%	27.72%
ENSG	75Outperform	$10.80B	26.95	16.63%	0.14%	17.49%	19.82%
AVAH	72Outperform	$2.88B	9.86	150.05%	―	19.52%	1337.90%
PACS	71Outperform	$7.79B	28.61	25.77%	―	11.02%	62.56%
NHC	68Neutral	$3.27B	28.55	10.41%	1.25%	5.71%	12.44%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:1ZU and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1ZU	Pennant Group Inc	32.00	10.60	49.53%
ADUS	Addus HomeCare Corporation	125.49	14.71	13.28%
NHC	National Healthcare	210.38	85.62	68.63%
ENSG	The Ensign	186.19	9.15	5.17%
AVAH	Aveanna Healthcare Holdings Inc	13.09	4.55	53.28%
PACS	PACS Group Inc	50.06	39.36	367.85%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pennant Group AI Stock Analysis